Latest Breaking News On - Jasonp rhodes - Page 1 : comparemela.com

Dyne Therapeutics (NASDAQ:DYN) PT Raised to $42 00 at Chardan Capital

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Chardan Capital from $31.00 to $42.00 in a research report sent to investors on Tuesday, MarketBeat Ratings reports. They currently have a buy rating on the stock. Other equities research analysts also recently issued reports about the company. Stifel Nicolaus increased their price […]

United statesJasonp rhodesPiper sandlerStifel nicolausZurcher kantonalbank zurich cantonalbankJefferies financial groupSecurities exchange commissionRaymond james associatesDyne therapeutics company profileDyne therapeutics incYork mellon corpTd asset management incAllspring global investments holdingsDyne therapeuticsFree reportChardan capital

Dyne Therapeutics (NASDAQ:DYN) Earns Buy Rating from Chardan Capital

Dyne Therapeutics (NASDAQ:DYN) Earns Buy Rating from Chardan Capital
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesStifel nicolausJasonp rhodesJoshuat brummPiper sandlerSwiss national bankDyne therapeutics incMorgan stanleyInvestment advisorsSei investments coSecurities exchange commissionRussell investments group ltdProshare advisorsChardan capitalDyne therapeuticsFree report

Dyne Therapeutics (NASDAQ:DYN) Given Outperform Rating at Oppenheimer

Dyne Therapeutics (NASDAQ:DYN) Given Outperform Rating at Oppenheimer
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesJasonp rhodesRichard william scalzoStifel nicolausZurcher kantonalbank zurich cantonalbankPiper sandlerSecurities exchange commissionPrincipal financial group incAllspring global investments holdingsDyne therapeutics incMorgan stanleyChina universal asset management coWetzel investment advisors incDyne therapeuticsFree reportModerate buy

Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)

Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesWildon farwellJasonp rhodesPiper sandlerStifel nicolausAcuta capital partnersTd asset management incProfund advisorsDyne therapeutics incHermes incMorgan stanleySecurities exchange commissionChardan capitalDyne therapeuticsFree reportDyne therapeutic

Dyne Therapeutics (NASDAQ:DYN) Receives Outperform Rating from Oppenheimer

Dyne Therapeutics (NASDAQ:DYN) Receives Outperform Rating from Oppenheimer
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesJasonp rhodesWildon farwellStifel nicolausPiper sandlerDyne therapeutics company profileVivo capitalFcpm iii servicesDyne therapeutics incMorgan stanleyJennison associatesArmistice capitalSecurities exchange commissionDyne therapeuticsFree reportChardan capital